← 產業報告目錄

Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2026-06-17頁數 484報告編號 MD4870

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The market for transplant diagnostics is valued at around USD 5.61 billion in 2026 and is expected to reach USD 8.14 billion by 2031, at a growth rate of 7.8%. The growing number of organ transplantation procedures is driving the demand for various testing methods, including donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling. Additionally, the rising adoption of molecular diagnostic technologies, such as PCR (polymerase chain reaction) and NGS (next-generation sequencing), is further fueling market growth. These technologies offer advantages such as high procedural efficacy, quick turnaround times, and real-time sample analysis. Furthermore, increasing awareness of the benefits of molecular diagnostic techniques in reducing the risk of graft rejection and improving transplantation outcomes is also contributing to market expansion. “The diagnostic applications segment is expected to witness the fastest growth rate in the transplant diagnostics market, by application, during the forecast period.” Based on application, the transplant diagnostics market is divided into diagnostic applications and research applications. In 2025, the diagnostic applications segment is expected to experience the fastest growth in the transplant diagnostics market. This growth is primarily due to advancements in molecular assay techniques and the increasing use of these procedures for pathogen detection and histocompatibility testing. Additionally, the rising incidence of chronic diseases that require transplantation is boosting demand for transplant diagnostic products and services. There is also a greater risk of genetic disorders and pathogen infections following transplantation, which supports the need for effective donor-recipient compatibility testing and post-transplant monitoring. Furthermore, growing awareness of the importance of accurate transplant diagnostics in reducing the risks of graft rejection and improving transplantation outcomes is contributing to the expansion of this segment. “The solid organ transplantation segment accounted for the largest market share in the transplant diagnostics market, by type, in 2025.” Based on transplant type, the transplant diagnostics market is divided into solid organ transplantation, stem cell transplantation, soft tissue transplantation, and bone marrow transplantation. In 2025, the solid organ transplantation segment led the transplant diagnostics market. This segment's significant share is mainly due to the growing use of transplant diagnostic products for various purposes, including donor-recipient compatibility testing, infectious disease testing, histocompatibility testing, genomic profiling, and blood profiling during solid organ transplantation procedures. Moreover, the increasing number of organ transplantation procedures, supportive government regulations, the rising prevalence of chronic diseases and disorders requiring transplantation, and technological advancements in transplant diagnostics are further contributing to the growth of this segment. “The Asia Pacific is the fastest-growing market for transplant diagnostics during the forecast period.” Based on region, the transplant diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, the Asia Pacific region is expected to see the fastest growth in the transplant diagnostics market. This growth is primarily driven by increased healthcare spending, rapid advances in healthcare infrastructure, greater adoption of advanced diagnostic technologies, and significant economic growth in emerging Asia-Pacific countries. Additionally, factors such as a rising elderly population, an increased prevalence of chronic diseases requiring transplants, and growing government initiatives to modernize healthcare systems in countries like China, India, and Japan are further supporting market expansion. Furthermore, Japan's provision of universal healthcare coverage for transplantation-related procedures and the burgeoning medical tourism industry across Asia Pacific countries are also contributing to the growth of the transplant diagnostics market in the region. The breakup of the profile of primary participants in the transplant diagnostics market: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%) • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%) The key players in the molecular infectious disease testing market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), Werfen (Spain), Hologic, Inc. (US), Merck KGaA (Germany), Eurobio Scientific (France), Biofortuna Limited (UK), BAG Diagnostics GmbH (Germany), Fujirebio (Japan), HistoGenetics LLC (US), PacBio (US), TBG Biotechnology Corp (Taiwan), Scisco Genetics, Inc. (US), inno-train Diagnostik GmbH (Germany), Bionobis (France), Takara Bio Inc. (Japan), Krishgen Biosystems Private Limited (India), and Prolmmune Ltd. (UK). Research Coverage: This research report categorizes the transplant diagnostics market by product & service (reagents & consumables, instruments, and software & services), technology {molecular assays [PCR-based molecular assays (real-time PCR, sequence-specific primer-PCR, sequence-specific oligonucleotide-PCR, and other PCR-based molecular assays), sequencing-based molecular assays (Sanger sequencing, next-generation sequencing, and other sequencing-based molecular assays)] and non-molecular assays}, application {diagnostic applications [pre-transplantation diagnostics (infectious disease testing, histocompatibility testing, and blood profiling) and post-transplantation diagnostics] and research applications}, transplant type [solid organ transplantation (kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other organ transplantation), stem cell transplantation, soft tissue transplantation, and bone marrow transplantation], end user (hospitals & transplant centers, research & academic institutes, and independent reference laboratories), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). This report provides a comprehensive overview of the key factors driving growth in the transplant diagnostics market, including drivers, restraints, opportunities, and challenges. It offers an in-depth analysis of the major industry players, highlighting their business models, available solutions, key strategies, recent acquisitions, and agreements. Additionally, the report includes a competitive analysis of emerging startups in the transplant diagnostics market. Reasons to Buy this Report: The report will assist market leaders and new entrants in the transplant diagnostics industry by providing estimated revenue figures for the overall market and its subsegments. It aims to help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, opportunities, and challenges. The report provides insights into the following pointers: • Analysis of key drivers (increasing number of transplant procedures, advancements in molecular diagnostic technologies, increasing public-private funding for transplant research, and rising prevalence of infectious diseases), restraints (high cost of advanced molecular diagnostic techniques and limited access to advanced transplant diagnostic infrastructure in emerging economies), opportunities (increasing adoption of cross-matching and chimerism testing and growing awareness regarding organ donation and transplantation), and challenges (gap between organ donor availability and transplant demand) influencing the growth of the transplant diagnostics market. • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the transplant diagnostics market. • Market Development: Comprehensive information about lucrative markets; the report analyzes the transplant diagnostics market across varied regions. • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the transplant diagnostics market. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), and bioMérieux (France).
目錄 Table of Contents
1 INTRODUCTION 41 1.1 STUDY OBJECTIVES 41 1.2 MARKET DEFINITION 41 1.3 STUDY SCOPE 42 1.3.1 MARKETS COVERED & REGIONAL SCOPE 42 1.3.2 INCLUSIONS & EXCLUSIONS 43 1.3.3 YEARS CONSIDERED 44 1.4 CURRENCY CONSIDERED 44 1.5 STAKEHOLDERS 44 1.6 SUMMARY OF CHANGES 45 2 EXECUTIVE SUMMARY 46 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS 46 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS 47 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH 48 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 49 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 50 3 PREMIUM INSIGHTS 51 3.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW 51 3.2 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031 52 3.3 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031 52 3.4 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031 53 3.5 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2026 VS. 2031 53 3.6 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031 54 3.7 TRANSPLANT DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54 4 MARKET OVERVIEW 55 4.1 INTRODUCTION 55 4.2 MARKET DYNAMICS 56 4.2.1 DRIVERS 56 4.2.1.1 Increasing number of transplant procedures 56 4.2.1.2 Advancements in molecular diagnostic technologies 57 4.2.1.3 Increasing public-private funding for transplant research 58 4.2.1.4 Rising incidence of chronic diseases 59 4.2.2 RESTRAINTS 59 4.2.2.1 High cost of instruments and consumables 59 4.2.2.2 Limited access to advanced transplant diagnostic infrastructure in emerging economies 60 4.2.3 OPPORTUNITIES 61 4.2.3.1 Increasing adoption of cross-matching and chimerism testing 61 4.2.3.2 Growing awareness regarding organ donation and transplantation 61 4.2.4 CHALLENGES 62 4.2.4.1 Gap between organ donor availability and transplant demand 62 4.3 UNMET NEEDS & WHITE SPACES 63 4.3.1 UNMET NEEDS IN TRANSPLANT DIAGNOSTICS MARKET 63 4.3.2 WHITE SPACE OPPORTUNITIES 64 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 65 4.4.1 INTERCONNECTED MARKETS 65 4.4.2 CROSS-SECTOR OPPORTUNITIES 66 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS 67 4.5.1 KEY MOVES & STRATEGIC FOCUS 67 5 INDUSTRY TRENDS 68 5.1 PORTER’S FIVE FORCES ANALYSIS 68 5.1.1 BARGAINING POWER OF SUPPLIERS 69 5.1.2 BARGAINING POWER OF BUYERS 69 5.1.3 THREAT OF NEW ENTRANTS 69 5.1.4 THREAT OF SUBSTITUTES 70 5.1.5 INTENSITY OF COMPETITIVE RIVALRY 70 5.2 MACROECONOMIC INDICATORS 70 5.2.1 INTRODUCTION 70 5.2.2 GDP TRENDS & FORECAST 70 5.3 SUPPLY CHAIN ANALYSIS 74 5.4 VALUE CHAIN ANALYSIS 75 5.5 ECOSYSTEM ANALYSIS 77 5.6 PRICING ANALYSIS 78 5.6.1 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026 78 5.6.2 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 79 5.7 TRADE ANALYSIS 81 5.7.1 IMPORT SCENARIO (HS CODE 3822) 81 5.7.2 EXPORT SCENARIO (HS CODE 3822) 82 5.8 KEY CONFERENCES & EVENTS, 2026–2027 83 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84 5.10 INVESTMENT & FUNDING SCENARIO 84 5.11 IMPACT OF 2025 US TARIFFS ON TRANSPLANT DIAGNOSTICS MARKET 85 5.11.1 INTRODUCTION 85 5.11.2 KEY TARIFF RATES 85 5.11.3 PRICE IMPACT ANALYSIS 86 5.11.4 IMPACT ON REGION 86 5.11.4.1 North America 87 5.11.4.2 Europe 87 5.11.4.3 Asia Pacific 87 5.11.5 IMPACT ON END-USE INDUSTRIES 88 5.11.5.1 Hospitals & transplant centers 88 5.11.5.2 Research & academic institutes 88 5.11.5.3 Independent reference laboratories 88 6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 89 6.1 KEY EMERGING TECHNOLOGIES 89 6.1.1 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA) 89 6.1.2 DIGITAL PCR (DPCR) 89 6.2 COMPLEMENTARY TECHNOLOGIES 90 6.2.1 AI IN TRANSPLANT DIAGNOSTICS 90 6.2.2 BIOINFORMATICS 90 6.3 ADJACENT TECHNOLOGIES 91 6.3.1 LIQUID BIOPSY 91 6.3.2 DIGITAL PATHOLOGY 91 6.4 TECHNOLOGY/PRODUCT ROADMAP 92 6.5 PATENT ANALYSIS 94 6.5.1 LIST OF KEY PATENTS 95 6.6 FUTURE APPLICATIONS 96 6.7 IMPACT OF AI/GENERATIVE AI ON TRANSPLANT DIAGNOSTICS MARKET 97 6.7.1 INTRODUCTION 97 6.7.2 TOP USE CASES & MARKET POTENTIAL 98 6.7.3 KEY COMPANIES IMPLEMENTING AI 98 6.7.4 FUTURE OF AI 99 7 SUSTAINABILITY & REGULATORY LANDSCAPE 100 7.1 REGIONAL REGULATIONS & COMPLIANCE 100 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 7.2 SUSTAINABILITY INITIATIVES 102 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN TRANSPLANT DIAGNOSTICS 102 7.2.1.1 Eco-friendly initiatives 103 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES 103   8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 105 8.1 DECISION-MAKING PROCESS 105 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA 105 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 105 8.2.2 BUYING CRITERIA 106 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 107 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 108 8.5 MARKET PROFITABILITY 110 8.5.1 REVENUE POTENTIAL 110 8.5.2 COST DYNAMICS 110 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS 111 9 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES 112 9.1 INTRODUCTION 113 9.2 REAGENTS & CONSUMABLES 113 9.2.1 REAGENTS & CONSUMABLES TO BE LARGEST AND FASTEST-GROWING SEGMENT IN TRANSPLANT DIAGNOSTICS MARKET 113 9.3 INSTRUMENTS 116 9.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET 116 9.4 SOFTWARE & SERVICES 119 9.4.1 GROWING AUTOMATION & DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO SUPPORT MARKET GROWTH 119 10 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY 123 10.1 INTRODUCTION 124 10.2 MOLECULAR ASSAYS 124 10.2.1 PCR-BASED MOLECULAR ASSAYS 128 10.2.1.1 Real-time PCR 132 10.2.1.1.1 Smaller sample volume requirements compared to conventional PCR technologies to drive demand 132 10.2.1.2 Sequence-specific primer-PCR (SSP-PCR) 135 10.2.1.2.1 Growing public-private investments for research activities to support market growth 135 10.2.1.3 Sequence-specific oligonucleotide-PCR (SSO-PCR) 138 10.2.1.3.1 Wide adoption of technique in PCR-based molecular assays market to fuel growth 138 10.2.1.4 Other PCR-based molecular assays 141 10.2.2 SEQUENCING-BASED MOLECULAR ASSAYS 144 10.2.2.1 Sanger sequencing 148 10.2.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market 148 10.2.2.2 Next-generation sequencing (NGS) 151 10.2.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS 151 10.2.2.3 Other sequencing-based molecular assays 154 10.3 NON-MOLECULAR ASSAYS 157 10.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED TECHNIQUES TO HAMPER GROWTH 157 11 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 161 11.1 INTRODUCTION 162 11.2 DIAGNOSTIC APPLICATIONS 162 11.2.1 PRE-TRANSPLANTATION DIAGNOSTICS 166 11.2.1.1 Infectious disease testing 169 11.2.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market 169 11.2.1.2 Histocompatibility testing 172 11.2.1.2.1 Technological advancements and growing R&D activities to propel market 172 11.2.1.3 Blood profiling 175 11.2.1.3.1 Growing availability of molecular assay products to support market growth 175 11.2.2 POST-TRANSPLANTATION DIAGNOSTICS 178 11.2.2.1 Greater risk of disorders and infections post-transplantation to make diagnostics necessary step 178 11.3 RESEARCH APPLICATIONS 181 11.3.1 GROWING FUNDING FOR RESEARCH TO DRIVE MARKET 181 12 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE 185 12.1 INTRODUCTION 186 12.2 SOLID ORGAN TRANSPLANTATION 186 12.2.1 KIDNEY TRANSPLANTATION 190 12.2.1.1 Rising prevalence of kidney diseases to drive market 190 12.2.2 LIVER TRANSPLANTATION 193 12.2.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market 193 12.2.3 LUNG TRANSPLANTATION 196 12.2.3.1 Rising prevalence of chronic lung diseases to drive market 196 12.2.4 HEART TRANSPLANTATION 199 12.2.4.1 Increasing prevalence of chronic cardiac diseases to propel market 199 12.2.5 PANCREAS TRANSPLANTATION 202 12.2.5.1 Procedural complexity and risk of surgical complications to restrain growth 202 12.2.6 OTHER SOLID ORGAN TRANSPLANTATION 205 12.3 STEM CELL TRANSPLANTATION 208 12.3.1 RISING PROCEDURAL VOLUME AND GROWING RESEARCH ACTIVITIES TO DRIVE MARKET 208   12.4 SOFT TISSUE TRANSPLANTATION 211 12.4.1 TECHNOLOGICAL ADVANCEMENTS AND RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET 211 12.5 BONE MARROW TRANSPLANTATION 214 12.5.1 DEARTH OF WELL-TRAINED SURGEONS TO PERFORM BONE MARROW TRANSPLANTATION TO HINDER GROWTH 214 13 TRANSPLANT DIAGNOSTICS MARKET, BY END USER 218 13.1 INTRODUCTION 219 13.2 INDEPENDENT REFERENCE LABORATORIES 219 13.2.1 RISING CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET 219 13.3 HOSPITALS & TRANSPLANT CENTERS 222 13.3.1 GROWING PURCHASING POWER OF HOSPITALS & TRANSPLANT CENTERS TO SUPPORT MARKET GROWTH 222 13.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES 225 13.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS IN GENOMICS-BASED TRANSPLANT DIAGNOSTIC RESEARCH TO DRIVE MARKET 225 14 TRANSPLANT DIAGNOSTICS MARKET, BY REGION 230 14.1 INTRODUCTION 231 14.2 NORTH AMERICA 231 14.2.1 US 238 14.2.1.1 Growing organ transplantation activity to support market expansion 238 14.2.2 CANADA 243 14.2.2.1 Growing transplant programs to support market growth 243 14.3 EUROPE 248 14.3.1 GERMANY 254 14.3.1.1 Expanding donor registry network to fuel market growth 254 14.3.2 UK 259 14.3.2.1 Rising transplant demand to support market growth 259 14.3.3 FRANCE 264 14.3.3.1 Growing organ donation initiatives to drive growth 264 14.3.4 ITALY 269 14.3.4.1 Increasing organ donation rates to drive market growth 269 14.3.5 SPAIN 274 14.3.5.1 Strong organ donation system to support market growth 274 14.3.6 REST OF EUROPE 279 14.4 ASIA PACIFIC 284 14.4.1 CHINA 291 14.4.1.1 Expanding transplantation programs to drive market growth 291 14.4.2 JAPAN 296 14.4.2.1 Growing transplant waiting population to support market growth 296   14.4.3 INDIA 301 14.4.3.1 Rising transplant procedures to drive market growth 301 14.4.4 AUSTRALIA 306 14.4.4.1 Rising number of solid organ transplantation procedures to drive market 306 14.4.5 SOUTH KOREA 311 14.4.5.1 Large transplant waiting population to drive market growth 311 14.4.6 REST OF ASIA PACIFIC 316 14.5 LATIN AMERICA 321 14.5.1 BRAZIL 327 14.5.1.1 Expanding transplant programs to drive market growth 327 14.5.2 MEXICO 332 14.5.2.1 Growing medical tourism to support market growth 332 14.5.3 REST OF LATIN AMERICA 337 14.6 MIDDLE EAST & AFRICA 342 14.6.1 UAE 348 14.6.1.1 Expanding organ donation programs to drive market growth 348 14.6.2 SAUDI ARABIA 353 14.6.2.1 Strengthening transplantation capabilities to support market growth 353 14.6.3 REST OF MIDDLE EAST & AFRICA 358 14.6.4 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET VOLUME 363 15 COMPETITIVE LANDSCAPE 364 15.1 INTRODUCTION 364 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 364 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET 364 15.3 REVENUE ANALYSIS, 2023–2025 366 15.4 MARKET SHARE ANALYSIS, 2025 366 15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025 367 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 369 15.5.1 STARS 369 15.5.2 EMERGING LEADERS 369 15.5.3 PERVASIVE PLAYERS 369 15.5.4 PARTICIPANTS 369 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 371 15.5.5.1 Company footprint 371 15.5.5.2 Region footprint 371 15.5.5.3 Product & service footprint 372 15.5.5.4 Application footprint 372 15.5.5.5 End-user footprint 373   15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 374 15.6.1 PROGRESSIVE COMPANIES 374 15.6.2 RESPONSIVE COMPANIES 374 15.6.3 DYNAMIC COMPANIES 374 15.6.4 STARTING BLOCKS 374 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 376 15.6.5.1 Detailed list of key startups/SMEs 376 15.6.5.2 Competitive benchmarking of startups/SMEs (1/2) 376 15.6.5.3 Competitive benchmarking of startups/SMEs (2/2) 377 15.7 COMPANY VALUATION & FINANCIAL METRICS 377 15.7.1 FINANCIAL METRICS 377 15.7.2 COMPANY VALUATION 378 15.8 BRAND/PRODUCT COMPARISON 378 15.9 COMPETITIVE SCENARIO 379 15.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS 379 15.9.2 DEALS 381 15.9.3 EXPANSIONS 384 16 COMPANY PROFILES 386 16.1 KEY PLAYERS 386 16.1.1 THERMO FISHER SCIENTIFIC INC. 386 16.1.1.1 Business overview 386 16.1.1.2 Products offered 387 16.1.1.3 Recent developments 391 16.1.1.3.1 Product & service launches 391 16.1.1.3.2 Deals 391 16.1.1.3.3 Expansions 392 16.1.1.4 MnM view 393 16.1.1.4.1 Right to win 393 16.1.1.4.2 Strategic choices 393 16.1.1.4.3 Weaknesses & competitive threats 393 16.1.2 F. HOFFMANN-LA ROCHE LTD. 394 16.1.2.1 Business overview 394 16.1.2.2 Products offered 395 16.1.2.3 Recent developments 397 16.1.2.3.1 Product launches & approvals 397 16.1.2.3.2 Deals 398 16.1.2.4 MnM view 398 16.1.2.4.1 Right to win 398 16.1.2.4.2 Strategic choices 398 16.1.2.4.3 Weaknesses & competitive threats 398   16.1.3 BIO-RAD LABORATORIES, INC. 399 16.1.3.1 Business overview 399 16.1.3.2 Products offered 400 16.1.3.3 Recent developments 403 16.1.3.3.1 Product launches 403 16.1.3.3.2 Deals 403 16.1.3.4 MnM view 404 16.1.3.4.1 Right to win 404 16.1.3.4.2 Strategic choices 404 16.1.3.4.3 Weaknesses & competitive threats 404 16.1.4 QIAGEN N.V. 405 16.1.4.1 Business overview 405 16.1.4.2 Products offered 406 16.1.4.3 Recent developments 410 16.1.4.3.1 Product launches & approvals 410 16.1.4.3.2 Deals 410 16.1.4.4 MnM view 411 16.1.4.4.1 Right to win 411 16.1.4.4.2 Strategic choices 411 16.1.4.4.3 Weaknesses & competitive threats 411 16.1.5 BIOMÉRIEUX 412 16.1.5.1 Business overview 412 16.1.5.2 Products offered 413 16.1.5.3 Recent developments 415 16.1.5.3.1 Product launches & approvals 415 16.1.5.3.2 Deals 415 16.1.5.4 MnM view 416 16.1.5.4.1 Right to win 416 16.1.5.4.2 Strategic choices 416 16.1.5.4.3 Weaknesses & competitive threats 416 16.1.6 ILLUMINA, INC. 417 16.1.6.1 Business overview 417 16.1.6.2 Products offered 418 16.1.6.3 Recent developments 420 16.1.6.3.1 Deals 420 16.1.7 BECTON, DICKINSON AND COMPANY 421 16.1.7.1 Business overview 421 16.1.7.2 Products offered 422 16.1.7.3 Recent developments 423 16.1.7.3.1 Deals 423   16.1.8 CAREDX, INC. 424 16.1.8.1 Business overview 424 16.1.8.2 Products offered 425 16.1.8.3 Recent developments 427 16.1.8.3.1 Product launches 427 16.1.8.3.2 Deals 428 16.1.9 DIASORIN S.P.A. 429 16.1.9.1 Business overview 429 16.1.9.2 Products offered 430 16.1.9.3 Recent developments 431 16.1.9.3.1 Product launches 431 16.1.9.3.2 Deals 432 16.1.10 WERFEN 433 16.1.10.1 Business overview 433 16.1.10.2 Products offered 434 16.1.10.3 Recent developments 435 16.1.10.3.1 Product launches 435 16.1.10.3.2 Deals 435 16.1.11 MERCK KGAA 436 16.1.11.1 Business overview 436 16.1.11.2 Products offered 437 16.1.11.3 Recent developments 438 16.1.11.3.1 Deals 438 16.1.11.3.2 Expansions 438 16.1.12 HOLOGIC, INC. 440 16.1.12.1 Business overview 440 16.1.12.2 Products offered 441 16.2 OTHER PLAYERS 442 16.2.1 EUROBIO SCIENTIFIC 442 16.2.2 BIOFORTUNA LIMITED 443 16.2.3 BAG DIAGNOSTICS GMBH 444 16.2.4 FUJIREBIO 445 16.2.5 HISTOGENETICS LLC 446 16.2.6 PACBIO 447 16.2.7 TBG BIOTECHNOLOGY CORP 448 16.2.8 SCISCO GENETICS, INC. 449 16.2.9 INNO-TRAIN DIAGNOSTIK GMBH 450 16.2.10 BIONOBIS 451 16.2.11 TAKARA BIO INC. 451 16.2.12 KRISHGEN BIOSYSTEMS PRIVATE LIMITED 452 16.2.13 PROIMMUNE LTD. 452 17 RESEARCH METHODOLOGY 453 17.1 RESEARCH DATA 453 17.1.1 SECONDARY DATA 454 17.1.1.1 List of secondary sources 454 17.1.1.2 Key data from secondary sources 455 17.1.2 PRIMARY DATA 455 17.1.2.1 List of primary sources 456 17.1.2.2 Key data from primary sources 456 17.1.2.3 Key industry insights 457 17.1.2.4 Breakdown of primary interviews 458 17.2 MARKET SIZE ESTIMATION 458 17.2.1 TOTAL MARKET SIZE: TRANSPLANT DIAGNOSTICS MARKET 458 17.2.2 BOTTOM-UP APPROACH 458 17.2.2.1 Approach 1: Revenue estimation of key players 459 17.2.2.2 Approach 2: Study of annual reports and investor presentations 459 17.2.2.3 Approach 3: Primary interviews 459 17.2.2.4 Growth forecast 460 17.2.2.5 CAGR projections 460 17.2.3 TOP-DOWN APPROACH 461 17.3 DATA TRIANGULATION 462 17.4 RESEARCH ASSUMPTIONS 463 17.4.1 STUDY-RELATED ASSUMPTIONS 463 17.5 STUDY ASSUMPTIONS 463 17.5.1 PARAMETRIC ASSUMPTIONS 464 17.5.2 GROWTH RATE ASSUMPTIONS 464 17.6 RESEARCH LIMITATIONS 464 17.7 RISK ASSESSMENT 465 18 APPENDIX 466 18.1 DISCUSSION GUIDE 466 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 480 18.3 CUSTOMIZATION OPTIONS 482 18.4 RELATED REPORTS 482 18.5 AUTHOR DETAILS 483
圖表清單 List of Tables & Figures
TABLE 1 TRANSPLANT DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 69 TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023–2030 71 TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS 72 TABLE 4 EUROPE: MACROECONOMIC INDICATORS 72 TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS 73 TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS 73 TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 73 TABLE 8 TRANSPLANT DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM 77 TABLE 9 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024–2026 (USD) 79 TABLE 10 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024–2026 (USD) 80 TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 81 TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021–2025 (USD MILLION) 82 TABLE 13 TRANSPLANT DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026–2027 83 TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES 85 TABLE 15 KEY PATENTS IN TRANSPLANT DIAGNOSTICS MARKET, 2022–2026 95 TABLE 16 KEY COMPANIES IMPLEMENTING AI IN TRANSPLANT DIAGNOSTICS MARKET 99 TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%) 106 TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 106 TABLE 24 ADOPTION BARRIERS & INTERNAL CHALLENGES 107 TABLE 25 TRANSPLANT DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES 109 TABLE 26 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 113 TABLE 27 TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2024–2031 (USD MILLION) 114 TABLE 28 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 114 TABLE 29 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 30 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 115 TABLE 31 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 32 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024–2031 (USD MILLION) 116 TABLE 33 TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024–2031 (USD MILLION) 117 TABLE 34 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 117 TABLE 35 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 36 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 118 TABLE 37 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 38 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024–2031 (USD MILLION) 119 TABLE 39 TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024–2031 (USD MILLION) 120 TABLE 40 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 120 TABLE 41 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 42 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 121 TABLE 43 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 44 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024–2031 (USD MILLION) 122 TABLE 45 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 124 TABLE 46 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 125 TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 125 TABLE 48 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 49 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 126 TABLE 50 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 51 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 127 TABLE 52 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 128 TABLE 53 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 129 TABLE 54 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 129 TABLE 55 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 56 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 130 TABLE 57 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 58 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 131 TABLE 59 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 132 TABLE 60 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2024–2031 (USD MILLION) 133 TABLE 61 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 133 TABLE 62 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 63 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 134 TABLE 64 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 65 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024–2031 (USD MILLION) 135 TABLE 66 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024–2031 (USD MILLION) 136 TABLE 67 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 136 TABLE 68 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 69 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 137 TABLE 70 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 71 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 138 TABLE 72 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024–2031 (USD MILLION) 139 TABLE 73 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 139 TABLE 74 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 75 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 140 TABLE 76 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 77 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024–2031 (USD MILLION) 141 TABLE 78 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 142 TABLE 79 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 142 TABLE 80 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 81 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 143 TABLE 82 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 83 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 144 TABLE 84 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 145 TABLE 85 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 145 TABLE 86 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 87 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 146 TABLE 88 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 89 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 147 TABLE 90 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 148 TABLE 91 TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 149 TABLE 92 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 149 TABLE 93 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 94 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 150 TABLE 95 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 96 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 151 TABLE 97 TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024–2031 (USD MILLION) 152 TABLE 98 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 152 TABLE 99 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 100 ASIA PACIFIC: TRANSPLANT DIAGNOSTICSARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 153 TABLE 101 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 102 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024–2031 (USD MILLION) 154 TABLE 103 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 155 TABLE 104 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 155 TABLE 105 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 156 TABLE 107 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 108 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 157 TABLE 109 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2024–2031 (USD MILLION) 158 TABLE 110 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 158 TABLE 111 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 112 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 159 TABLE 113 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 114 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024–2031 (USD MILLION) 160 TABLE 115 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 162 TABLE 116 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 163 TABLE 117 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 163 TABLE 118 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 119 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 164 TABLE 120 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 121 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 165 TABLE 122 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 166 TABLE 123 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 166 TABLE 124 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 167 TABLE 125 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 167 TABLE 126 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 127 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 168 TABLE 128 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 129 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 169 TABLE 130 TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2024–2031 (USD MILLION) 170 TABLE 131 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 170 TABLE 132 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 133 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 171 TABLE 134 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 135 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 172 TABLE 136 TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY REGION, 2024–2031 (USD MILLION) 173 TABLE 137 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 173 TABLE 138 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 139 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 174 TABLE 140 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 141 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024–2031 (USD MILLION) 175 TABLE 142 TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY REGION, 2024–2031 (USD MILLION) 176 TABLE 143 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 176 TABLE 144 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 145 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 177 TABLE 146 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 147 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024–2031 (USD MILLION) 178 TABLE 148 TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 179 TABLE 149 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 179 TABLE 150 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 151 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 180 TABLE 152 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 153 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024–2031 (USD MILLION) 181 TABLE 154 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024–2031 (USD MILLION) 182 TABLE 155 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 182 TABLE 156 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 157 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 183 TABLE 158 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 159 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024–2031 (USD MILLION) 184 TABLE 160 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 186 TABLE 161 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 187 TABLE 162 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 187 TABLE 163 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 164 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 188 TABLE 165 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 166 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 189 TABLE 167 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 190 TABLE 168 TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 191 TABLE 169 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 191 TABLE 170 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 171 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 192 TABLE 172 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 173 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 193 TABLE 174 TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 194 TABLE 175 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 194 TABLE 176 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 177 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 195 TABLE 178 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 179 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 196 TABLE 180 TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 197 TABLE 181 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 197 TABLE 182 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 183 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 198 TABLE 184 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 185 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 199 TABLE 186 TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 200 TABLE 187 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 200 TABLE 188 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 189 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 201 TABLE 190 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 191 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 202 TABLE 192 TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 203 TABLE 193 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 203 TABLE 194 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 195 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 204 TABLE 196 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 197 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 205 TABLE 198 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 206 TABLE 199 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 206 TABLE 200 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 201 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 207 TABLE 202 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 203 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 208 TABLE 204 TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 209 TABLE 205 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 209 TABLE 206 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 207 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 210 TABLE 208 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 209 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 211 TABLE 210 TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 212 TABLE 211 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 212 TABLE 212 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 213 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 213 TABLE 214 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 215 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 214 TABLE 216 TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY REGION, 2024–2031 (USD MILLION) 215 TABLE 217 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 215 TABLE 218 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 219 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 216 TABLE 220 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 221 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024–2031 (USD MILLION) 217 TABLE 222 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 219 TABLE 223 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024–2031 (USD MILLION) 220 TABLE 224 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 220 TABLE 225 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 226 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 221 TABLE 227 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 228 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024–2031 (USD MILLION) 222 TABLE 229 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024–2031 (USD MILLION) 223 TABLE 230 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 223 TABLE 231 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 232 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 224 TABLE 233 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 234 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024–2031 (USD MILLION) 225 TABLE 235 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024–2031 (USD MILLION) 226 TABLE 236 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 237 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 227 TABLE 238 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 239 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 228 TABLE 240 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024–2031 (USD MILLION) 229 TABLE 241 TRANSPLANT DIAGNOSTICS, BY REGION, 2024–2031 (USD MILLION) 231 TABLE 242 NORTH AMERICA: MACROECONOMIC INDICATORS 232 TABLE 243 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 233 TABLE 244 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 233 TABLE 245 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 233 TABLE 246 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 247 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 234 TABLE 248 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 249 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 235 TABLE 250 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 235 TABLE 251 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 252 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 236 TABLE 253 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 237 TABLE 254 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 237 TABLE 255 US: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 239 TABLE 256 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 239 TABLE 257 US: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 239 TABLE 258 US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 259 US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 240 TABLE 260 US: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 241 TABLE 261 US: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 262 US: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 241 TABLE 263 US: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 264 US: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 242 TABLE 265 US: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 243 TABLE 266 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 244 TABLE 267 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 244 TABLE 268 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 244 TABLE 269 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 270 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 245 TABLE 271 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 246 TABLE 272 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 273 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 246 TABLE 274 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 275 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 247 TABLE 276 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 248 TABLE 277 MACROECONOMIC INDICATORS FOR EUROPE 249 TABLE 278 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 249 TABLE 279 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 250 TABLE 280 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 250 TABLE 281 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 250 TABLE 282 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 283 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 251 TABLE 284 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 252 TABLE 285 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 286 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 252 TABLE 287 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 288 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 253 TABLE 289 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 254 TABLE 290 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 255 TABLE 291 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 255 TABLE 292 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 255 TABLE 293 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 294 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 256 TABLE 295 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 257 TABLE 296 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 297 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 257 TABLE 298 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 299 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 258 TABLE 300 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 259 TABLE 301 UK: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 260 TABLE 302 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 260 TABLE 303 UK: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 260 TABLE 304 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 305 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 261 TABLE 306 UK: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 262 TABLE 307 UK: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 308 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 262 TABLE 309 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 310 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 263 TABLE 311 UK: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 264 TABLE 312 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 265 TABLE 313 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 265 TABLE 314 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 265 TABLE 315 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 316 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 266 TABLE 317 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 267 TABLE 318 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 319 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 267 TABLE 320 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 321 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 268 TABLE 322 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 269 TABLE 323 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 270 TABLE 324 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 270 TABLE 325 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 270 TABLE 326 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 327 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 271 TABLE 328 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 272 TABLE 329 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 330 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 272 TABLE 331 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 332 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 273 TABLE 333 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 274 TABLE 334 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 275 TABLE 335 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 275 TABLE 336 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 275 TABLE 337 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 338 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 276 TABLE 339 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 277 TABLE 340 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 341 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 277 TABLE 342 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 343 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 278 TABLE 344 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 279 TABLE 345 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 280 TABLE 346 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 280 TABLE 347 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 280 TABLE 348 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 349 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 281 TABLE 350 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 282 TABLE 351 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 352 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 282 TABLE 353 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 354 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 283 TABLE 355 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 284 TABLE 356 MACROECONOMIC INDICATORS FOR ASIA PACIFIC 285 TABLE 357 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 286 TABLE 358 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 286 TABLE 359 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 287 TABLE 360 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 287 TABLE 361 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 362 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 288 TABLE 363 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 289 TABLE 364 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 365 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 289 TABLE 366 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 367 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 290 TABLE 368 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 291 TABLE 369 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 292 TABLE 370 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 292 TABLE 371 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 292 TABLE 372 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 373 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 293 TABLE 374 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 294 TABLE 375 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 376 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 294 TABLE 377 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 378 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 295 TABLE 379 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 296 TABLE 380 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 297 TABLE 381 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 297 TABLE 382 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 297 TABLE 383 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 384 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 298 TABLE 385 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 299 TABLE 386 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 387 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 299 TABLE 388 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 389 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 300 TABLE 390 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 301 TABLE 391 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 302 TABLE 392 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 302 TABLE 393 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 302 TABLE 394 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 395 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 303 TABLE 396 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 304 TABLE 397 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 398 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 304 TABLE 399 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 400 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 305 TABLE 401 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 306 TABLE 402 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 307 TABLE 403 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 307 TABLE 404 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 307 TABLE 405 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 406 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 308 TABLE 407 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 309 TABLE 408 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 409 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 309 TABLE 410 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 411 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 310 TABLE 412 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 311 TABLE 413 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 312 TABLE 414 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 312 TABLE 415 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 312 TABLE 416 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 417 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 313 TABLE 418 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 314 TABLE 419 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 420 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 314 TABLE 421 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 422 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 315 TABLE 423 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 316 TABLE 424 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 317 TABLE 425 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 317 TABLE 426 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 317 TABLE 427 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 428 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 318 TABLE 429 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 319 TABLE 430 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 431 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 319 TABLE 432 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 433 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 320 TABLE 434 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 321 TABLE 435 MACROECONOMIC INDICATORS FOR LATIN AMERICA 322 TABLE 436 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 322 TABLE 437 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 322 TABLE 438 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 323 TABLE 439 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 323 TABLE 440 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 441 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 324 TABLE 442 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 325 TABLE 443 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 444 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 325 TABLE 445 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 446 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 326 TABLE 447 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 327 TABLE 448 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 328 TABLE 449 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 328 TABLE 450 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 328 TABLE 451 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 452 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 329 TABLE 453 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 330 TABLE 454 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 455 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 330 TABLE 456 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 457 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 331 TABLE 458 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 332 TABLE 459 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 333 TABLE 460 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 333 TABLE 461 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 333 TABLE 462 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 463 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 334 TABLE 464 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 335 TABLE 465 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 466 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 335 TABLE 467 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 468 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 336 TABLE 469 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 337 TABLE 470 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 338 TABLE 471 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 338 TABLE 472 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 338 TABLE 473 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 474 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 339 TABLE 475 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 340 TABLE 476 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 477 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 340 TABLE 478 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 479 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 341 TABLE 480 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 342 TABLE 481 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA 343 TABLE 482 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024–2031 (USD MILLION) 343 TABLE 483 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 343 TABLE 484 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 344 TABLE 485 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 344 TABLE 486 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 487 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 345 TABLE 488 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 346 TABLE 489 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 490 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 346 TABLE 491 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 492 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 347 TABLE 493 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 348 TABLE 494 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 349 TABLE 495 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 349 TABLE 496 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 349 TABLE 497 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 498 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 350 TABLE 499 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 351 TABLE 500 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 501 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 351 TABLE 502 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 503 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 352 TABLE 504 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 353 TABLE 505 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 354 TABLE 506 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 354 TABLE 507 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 354 TABLE 508 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 509 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 355 TABLE 510 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 356 TABLE 511 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 512 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 356 TABLE 513 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 514 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 357 TABLE 515 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 358 TABLE 516 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024–2031 (USD MILLION) 359 TABLE 517 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024–2031 (USD MILLION) 359 TABLE 518 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 359 TABLE 519 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 520 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024–2031 (USD MILLION) 360 TABLE 521 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024–2031 (USD MILLION) 361 TABLE 522 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 523 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024–2031 (USD MILLION) 361 TABLE 524 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 525 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024–2031 (USD MILLION) 362 TABLE 526 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031 (USD MILLION) 363 TABLE 527 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET, BY TYPE, 2024–2031 (IN THOUSAND) 363 TABLE 528 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN TRANSPLANT DIAGNOSTICS MARKET, JANUARY 2023−APRIL 2026 364 TABLE 529 TRANSPLANT DIAGNOSTICS MARKET: DEGREE OF COMPETITION 367 TABLE 530 TRANSPLANT DIAGNOSTICS MARKET: REGION FOOTPRINT 371 TABLE 531 TRANSPLANT DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT 372 TABLE 532 TRANSPLANT DIAGNOSTICS MARKET: APPLICATION FOOTPRINT 372 TABLE 533 TRANSPLANT DIAGNOSTICS MARKET: END-USER FOOTPRINT 373 TABLE 534 TRANSPLANT DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES 376 TABLE 535 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2) 376 TABLE 536 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2) 377 TABLE 537 TRANSPLANT DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 379 TABLE 538 TRANSPLANT DIAGNOSTICS MARKET: DEALS, JANUARY 2023–APRIL 2026 381 TABLE 539 TRANSPLANT DIAGNOSTICS MARKET: EXPANSION, JANUARY 2023–APRIL 2026 384 TABLE 540 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 386 TABLE 541 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED 387 TABLE 542 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023–APRIL 2026 391 TABLE 543 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023–APRIL 2026 391 TABLE 544 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–APRIL 2025 392 TABLE 545 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 394 TABLE 546 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 395 TABLE 547 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 397 TABLE 548 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023–APRIL 2026 398 TABLE 549 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 399 TABLE 550 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 400 TABLE 551 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 403 TABLE 552 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023–APRIL 2026 403 TABLE 553 QIAGEN N.V.: COMPANY OVERVIEW 405 TABLE 554 QIAGEN N.V.: PRODUCTS OFFERED 406 TABLE 555 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 410 TABLE 556 QIAGEN N.V.: DEALS, JANUARY 2023–APRIL 2026 410 TABLE 557 BIOMÉRIEUX: COMPANY OVERVIEW 412 TABLE 558 BIOMÉRIEUX: PRODUCTS OFFERED 413 TABLE 559 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023–APRIL 2026 415 TABLE 560 BIOMÉRIEUX: DEALS, JANUARY 2023–APRIL 2026 415 TABLE 561 ILLUMINA, INC.: COMPANY OVERVIEW 417 TABLE 562 ILLUMINA, INC.: PRODUCTS OFFERED 418 TABLE 563 ILLUMINA, INC.: DEALS, JANUARY 2023–APRIL 2026 420 TABLE 564 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 421 TABLE 565 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 422 TABLE 566 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023–APRIL 2026 423 TABLE 567 CAREDX, INC.: COMPANY OVERVIEW 424 TABLE 568 CAREDX, INC.: PRODUCTS OFFERED 425 TABLE 569 CAREDX, INC.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 427 TABLE 570 CAREDX, INC.: DEALS, JANUARY 2023–APRIL 2026 428 TABLE 571 DIASORIN S.P.A.: COMPANY OVERVIEW 429 TABLE 572 DIASORIN S.P.A.: PRODUCTS OFFERED 430 TABLE 573 DIASORIN S.P.A.: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 431 TABLE 574 DIASORIN S.P.A.: DEALS, JANUARY 2023–APRIL 2026 432 TABLE 575 WERFEN: COMPANY OVERVIEW 433 TABLE 576 WERFEN: PRODUCTS OFFERED 434 TABLE 577 WERFEN: PRODUCT LAUNCHES, JANUARY 2023–APRIL 2026 435 TABLE 578 WERFEN: DEALS, JANUARY 2023–APRIL 2026 435 TABLE 579 MERCK KGAA: COMPANY OVERVIEW 436 TABLE 580 MERCK KGAA: PRODUCTS OFFERED 437 TABLE 581 MERCK KGAA: DEALS, JANUARY 2023–APRIL 2026 438 TABLE 582 MERCK KGAA: EXPANSIONS, JANUARY 2023–APRIL 2026 438 TABLE 583 HOLOGIC, INC.: COMPANY OVERVIEW 440 TABLE 584 HOLOGIC, INC.: PRODUCTS OFFERED 441 TABLE 585 EUROBIO SCIENTIFIC: COMPANY OVERVIEW 442 TABLE 586 BIOFORTUNA LIMITED: COMPANY OVERVIEW 443 TABLE 587 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW 444 TABLE 588 FUJIREBIO: COMPANY OVERVIEW 445 TABLE 589 HISTOGENETICS LLC: COMPANY OVERVIEW 446 TABLE 590 PACBIO: COMPANY OVERVIEW 447 TABLE 591 TBG BIOTECHNOLOGY CORP: COMPANY OVERVIEW 448 TABLE 592 SCISCO GENETICS, INC.: COMPANY OVERVIEW 449 TABLE 593 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW 450 TABLE 594 BIONOBIS: COMPANY OVERVIEW 451 TABLE 595 TAKARA BIO INC.: COMPANY OVERVIEW 451 TABLE 596 KRISHGEN BIOSYSTEMS PRIVATE LIMITED: COMPANY OVERVIEW 452 TABLE 597 PROIMMUNE LTD.: COMPANY OVERVIEW 452 TABLE 598 TRANSPLANT DIAGNOSTICS MARKET: RISK ASSESSMENT 465 FIGURE 1 TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE 42 FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS 46 FIGURE 3 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, 2024–2031 46 FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023–2025 47 FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF TRANSPLANT DIAGNOSTICS MARKET 48 FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN TRANSPLANT DIAGNOSTICS MARKET, 2025 49 FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 50 FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET 51 FIGURE 9 REAGENTS & CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 52 FIGURE 10 MOLECULAR ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 52 FIGURE 11 DIAGNOSTIC APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 53 FIGURE 12 SOLID ORGAN TRANSPLANTATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD 53 FIGURE 13 INDEPENDENT REFERENCE LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD 54 FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 54 FIGURE 15 TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 FIGURE 16 TRANSPLANT DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 68 FIGURE 17 TRANSPLANT DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 75 FIGURE 18 TRANSPLANT DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS 76 FIGURE 19 TRANSPLANT DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS 77 FIGURE 20 TRANSPLANT DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 84 FIGURE 21 NUMBER OF DEALS & FUNDING ACTIVITIES IN TRANSPLANT DIAGNOSTICS MARKET 85 FIGURE 22 PATENT ANALYSIS FOR TRANSPLANT DIAGNOSTICS, JANUARY 2016–DECEMBER 2025 94 FIGURE 23 MARKET POTENTIAL OF AI IN TRANSPLANT DIAGNOSTICS MARKET 98 FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE 105 FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE 106 FIGURE 26 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT 232 FIGURE 27 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT 285 FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023–2025 (USD MILLION) 366 FIGURE 29 TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL) 367 FIGURE 30 TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025 370 FIGURE 31 TRANSPLANT DIAGNOSTICS MARKET: COMPANY FOOTPRINT 371 FIGURE 32 TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025 375 FIGURE 33 EV/EBITDA OF KEY VENDORS 377 FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 378 FIGURE 35 TRANSPLANT DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR TRANSPLANT INSTRUMENTS 378 FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025) 387 FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025) 395 FIGURE 38 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025) 400 FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2025) 406 FIGURE 40 BIOMÉRIEUX: COMPANY SNAPSHOT (2025) 413 FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2025) 418 FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025) 422 FIGURE 43 CAREDX, INC.: COMPANY SNAPSHOT (2025) 425 FIGURE 44 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025) 430 FIGURE 45 WERFEN: COMPANY SNAPSHOT (2025) 434 FIGURE 46 MERCK KGAA: COMPANY SNAPSHOT (2025) 437 FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2025) 441 FIGURE 48 RESEARCH DESIGN 453 FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 458 FIGURE 50 TOP-DOWN APPROACH 461 FIGURE 51 DATA TRIANGULATION 462

同分類最新報告（醫療器材）

查看醫療器材全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們